tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Invivyd Unveils Promising RSV Antibody Candidate

Story Highlights
Invivyd Unveils Promising RSV Antibody Candidate

TipRanks Black Friday Sale

Invivyd ( (IVVD) ) has provided an update.

On November 24, 2025, Invivyd, Inc. announced the selection of VBY329, a potential best-in-class monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) in newborns, infants, and children. VBY329, developed using Invivyd’s proprietary technology, shows higher potency and improved resistance compared to existing RSV treatments. The company aims for IND readiness by the second half of 2026, targeting the growing pediatric RSV prophylaxis market, which is expected to reach $3-$4 billion globally by 2030. This development could significantly enhance Invivyd’s industry positioning by providing a novel solution in a rapidly expanding market.

The most recent analyst rating on (IVVD) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Spark’s Take on IVVD Stock

According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.

Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.

To see Spark’s full report on IVVD stock, click here.

More about Invivyd

Invivyd, Inc. is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary technology platform to develop best-in-class antibodies, and it received emergency use authorization from the U.S. FDA in March 2024 for a monoclonal antibody in its pipeline.

Average Trading Volume: 10,669,672

Technical Sentiment Signal: Buy

Current Market Cap: $582.8M

See more data about IVVD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1